Lateral Pharma discovers new target for treating chronic neuropathic pain (opens in new tab)

Lateral Pharma announced that peer-reviewed research published online in PAIN identifies Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain and reports that LAT8881, the company’s first-generation Stressed Cell Protectant peptide, acts via LanCL1. The paper, titled Lanthionine synthetase C-like protein 1 (LanCL1): a therapeutic target for neuropathic pain, was […] The post appeared first on <a href="